Industries

Cipla to Acquire Inzpera Healthsciences for ₹110.65 Crore, Bolstering Paediatric & Wellness Portfolio

Cipla to Acquire Inzpera Healthsciences for ₹110.65 Crore, Bolstering Paediatric & Wellness Portfolio

Pharm'Up

Pharmaceutical major Cipla Limited has officially announced its strategic move to significantly enhance its footprint in the...

Novo Nordisk Surges on 41% Obesity Sales Growth and Strategic MASH Pipeline Expansion, Despite DKK 9 Billion Restructuring Hit

Novo Nordisk Surges on 41% Obesity Sales Growth and Strategic MASH Pipeline Expansion, Despite DKK 9 Billion Restructuring Hit

Pharm'Up

Novo Nordisk A/S, the Danish pharmaceutical giant, today released a robust financial report for the first nine...

Merck Secures $700 Million from Blackstone to Accelerate Development of Next-Generation TROP2 ADC, Sacituzumab Tirumotecan

Merck Secures $700 Million from Blackstone to Accelerate Development of Next-Generation TROP2 ADC, Sacituzumab Tirumotecan

Pharm'Up

A significant financial collaboration has been finalized to dramatically accelerate the clinical development of sacituzumab tirumotecan (sac-TMT),...

NATCO Pharma Wins Legal Battle Against Roche to Launch Affordable Risdiplam for Spinal Muscular Atrophy in India

NATCO Pharma Wins Legal Battle Against Roche to Launch Affordable Risdiplam for Spinal Muscular Atrophy in India

Pharm'Up

NATCO Pharma Limited announced a major legal victory in its ongoing patent dispute with pharmaceutical giant Roche....

AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing

AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing

Pharm'Up

AstraZeneca has announced a landmark agreement with President Donald J. Trump’s administration aimed at significantly reducing prescription...

Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials

Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials

Pharm'Up

Eli Lilly and Company announced positive topline results from two pivotal Phase 3 trials, ACHIEVE-2 and ACHIEVE-5,...

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Pharm'Up

Biocon Biologics Ltd (BBL), a global biosimilars company, announced that it received a Notice of Compliance (NOC)...

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Pharm'Up

Novartis announced a definitive agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based biopharmaceutical company...

Pfizer Sues Metsera and Novo Nordisk in Delaware, Alleging Breach of Merger Deal and Anticompetitive Conspiracy

Pfizer Sues Metsera and Novo Nordisk in Delaware, Alleging Breach of Merger Deal and Anticompetitive Conspiracy

Pharm'Up

Pfizer Inc. has escalated its battle with competitor Novo Nordisk A/S by filing a major lawsuit against...

USFDA Grants Tentative Approval to Zydus Lifesciences for Generic Crohn’s Disease Drug (Budesonide 4mg)

USFDA Grants Tentative Approval to Zydus Lifesciences for Generic Crohn’s Disease Drug (Budesonide 4mg)

Pharm'Up

Zydus Lifesciences Limited (Zydus) has achieved a significant regulatory milestone, securing tentative approval from the United States...

Cipla to Acquire Inzpera Healthsciences for ₹110.65 Crore, Bolstering Paediatric & Wellness Portfolio

Novo Nordisk Surges on 41% Obesity Sales Growth and Strategic MASH Pipeline Expansion, Despite DKK 9 Billion Restructuring Hit

Merck Secures $700 Million from Blackstone to Accelerate Development of Next-Generation TROP2 ADC, Sacituzumab Tirumotecan

NATCO Pharma Wins Legal Battle Against Roche to Launch Affordable Risdiplam for Spinal Muscular Atrophy in India

AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing

Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Pfizer Sues Metsera and Novo Nordisk in Delaware, Alleging Breach of Merger Deal and Anticompetitive Conspiracy

USFDA Grants Tentative Approval to Zydus Lifesciences for Generic Crohn’s Disease Drug (Budesonide 4mg)

Read These Too

Navigating Balance Disorders: Causes, Symptoms, and Management

Understanding Seasonal Allergic Rhinitis: Causes, Symptoms, and Relief

Pharmacovigilance Specialist Opportunity at Bausch + Lomb

Career Opportunity: Formulation & Development (Injectable) at Derren Healthcare